Berlin, Germany, February 13, 2025 – Data from the first-in-human radioligand-therapy for muscle invasive bladder cancer (MIBC) using Pentixapharm's Lu177-PentixaTher compound will be shown at the ...

ConferenceFirst-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025 13.02.2025 / 14:10 CET/CESTThe issuer is ...

The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.

Using the Decipher Bladder test to determine each tumor’s molecular subtype, researchers found that NMIBC patients with ...

A bladder cancer diagnosis can be overwhelming bringing uncertainty and emotional distress Read on to learn the hopes and ...

The most common symptom is blood in the urine (hematuria), which may appear pink, red, or brown. Other signs include frequent ...

Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

“You will be able to put a patient in there with a given tumor and then toggle between wedge resection, segmentectomy and lobectomy and see how not only your short-term outcomes would change ...

Local complete resection rates for EMR and ESD according to tumor size and location are shown in Table 3. When lesions were 5 mm or less in diameter, complete resection rates did not differ ...

In bladder cancer, the majority of published data available ... 39 In a later, larger study of 82 patients with NMIBC who were treated with transurethral resection and immunotherapy, tumor-informed ...

It was there that a biopsy uncovered the truth: Armando had Stage 4 metastatic urothelial carcinoma (mUC), also known as advanced bladder cancer. Bladder cancer is a serious, challenging disease ...

and colleagues conducted a prospective open-label randomized study within 17 U.K. hospitals involving patients with suspected new bladder cancer who were randomly assigned to transurethral ...